Products

Gene therapy is coming of age, offering hope to millions of patients, and offering opportunities for those eager to invest in innovation for health.

AMT is now well positioned to address the urgent needs of many patients suffering from diseases for which no or suboptimal therapeutic solutions exist today. Many, but not all of these diseases are rare, are “orphans”. People affected by these diseases have little prospect of seeing a novel therapy because current drug development processes require too much time and resources to provide pharmaceutical companies with a sufficient return on their investment.

Gene therapy, and the flexibility of AMT’s platform, offer the hope of bringing more curative or causal therapies to patients faster. Furthermore, although orphan drugs target a smaller patient population than non-orphan drugs, “rare” is a relative term. In the United States alone, according to the National Institutes of Health (NIH) as many as 25 million people are affected by one of the 5,000 orphan disease currently diagnosed. This makes orphan diseases – and finding real therapeutic solutions for them – a serious public health concern.

Over the past decade it has become obvious that developing safe and efficacious therapies for orphans may also lead to substantial revenue generation. The best selling drug developed for an orphan indication is Erythropoetin (EPO). EPO has been subsequently expanded to target a number of indications, and in 2008 Amgen sold $ 5.6 billion of EPO products.

DISCLAIMER – IMPORTANT

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V. IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

Please read this notice carefully - it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.

Non-Dutch persons

Viewing the materials made available on this website may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to access such materials. Any person resident outside the Netherlands who wishes to access these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

The materials made available on this website do not contain, constitute or form part of, and should not be construed as, an offer, or the invitation or solicitation to subscribe for or purchase any securities ("Securities") mentioned in the materials and nothing contained herein shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The Securities have not been (nor will be) registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

No Securities will be offered or allotted directly or indirectly into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States, unless an exemption from registration under the US Securities Act, is available. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. Accordingly, copies of materials made available on this website and any related documents will not and must not be mailed or otherwise transmitted, distributed or forwarded in or into the United States.

The materials contained herein have not been submitted to or reviewed by the US Securities and Exchange Commission (the "SEC") or any state securities commission of any other jurisdiction, and neither the SEC nor any such state securities commission of any other jurisdiction has (a) approved or disapproved, (b) passed upon the merits or fairness of, or (c) passed upon the adequacy or accuracy of the disclosure of any materials contained herein. Any representation to the contrary is a criminal offence in the United States.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to these materials is being made available on this webpage by Amsterdam Molecular Therapeutics (AMT) Holding N.V. in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Amsterdam Molecular Therapeutics (AMT) Holding N.V. that they are doing so for information purposes only.

Neither any press announcement nor any other document made available on this website constitutes an offer to sell, an invitation to induce an offer or the solicitation of an offer to acquire, Securities in Amsterdam Molecular Therapeutics (AMT) Holding N.V. or Kairos Therapeutics B.V. and cannot be relied upon for any investment contract or decision. Furthermore, such documents do not constitute a recommendation by Amsterdam Molecular Therapeutics (AMT) Holding N.V. or any other party to sell or buy Securities.

Unless otherwise determined by Amsterdam Molecular Therapeutics (AMT) Holding N.V. and permitted by applicable law and regulation, copies of the contents of the following pages (including documents posted thereon) are not being, and must not be, released or otherwise forwarded, distributed or sent in or into the United States or any other jurisdiction where their extension or availability (and/or any transaction contemplated thereby) would breach any applicable law, and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into the United States or any other jurisdiction where to do so would breach any applicable law.

Confirmation of understanding and acceptance of disclaimer

I certify that I am not located in the United States or any other jurisdiction where the release, publication or distribution of these materials would be unlawful.

I have read and understood the disclaimer set out above and agree to be bound by its terms.

I confirm that I am permitted under applicable law and regulation to proceed to the electronic versions of these materials and receive information of the kind contained in this website.

DISCLAIMER – IMPORTANT

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V. IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

Please read this notice carefully - it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.

Non-Dutch persons

Viewing the materials made available on this website may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to access such materials. Any person resident outside the Netherlands who wishes to access these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

The materials made available on this website do not contain, constitute or form part of, and should not be construed as, an offer, or the invitation or solicitation to subscribe for or purchase any securities ("Securities") mentioned in the materials and nothing contained herein shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The Securities have not been (nor will be) registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

No Securities will be offered or allotted directly or indirectly into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States, unless an exemption from registration under the US Securities Act, is available. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. Accordingly, copies of materials made available on this website and any related documents will not and must not be mailed or otherwise transmitted, distributed or forwarded in or into the United States.

The materials contained herein have not been submitted to or reviewed by the US Securities and Exchange Commission (the "SEC") or any state securities commission of any other jurisdiction, and neither the SEC nor any such state securities commission of any other jurisdiction has (a) approved or disapproved, (b) passed upon the merits or fairness of, or (c) passed upon the adequacy or accuracy of the disclosure of any materials contained herein. Any representation to the contrary is a criminal offence in the United States.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to these materials is being made available on this webpage by Amsterdam Molecular Therapeutics (AMT) Holding N.V. in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Amsterdam Molecular Therapeutics (AMT) Holding N.V. that they are doing so for information purposes only.

Neither any press announcement nor any other document made available on this website constitutes an offer to sell, an invitation to induce an offer or the solicitation of an offer to acquire, Securities in Amsterdam Molecular Therapeutics (AMT) Holding N.V. or Kairos Therapeutics B.V. and cannot be relied upon for any investment contract or decision. Furthermore, such documents do not constitute a recommendation by Amsterdam Molecular Therapeutics (AMT) Holding N.V. or any other party to sell or buy Securities.

Unless otherwise determined by Amsterdam Molecular Therapeutics (AMT) Holding N.V. and permitted by applicable law and regulation, copies of the contents of the following pages (including documents posted thereon) are not being, and must not be, released or otherwise forwarded, distributed or sent in or into the United States or any other jurisdiction where their extension or availability (and/or any transaction contemplated thereby) would breach any applicable law, and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into the United States or any other jurisdiction where to do so would breach any applicable law.

Confirmation of understanding and acceptance of disclaimer

I certify that I am not located in the United States or any other jurisdiction where the release, publication or distribution of these materials would be unlawful.

I have read and understood the disclaimer set out above and agree to be bound by its terms.

I confirm that I am permitted under applicable law and regulation to proceed to the electronic versions of these materials and receive information of the kind contained in this website.